Furthermore, tocilizumab, a potent Il6 receptor antagonist, has demonstrated robust anti-inflammatory efficacy in patients with non-ST-segment elevation myocardial infarction, as evidenced by substantial reductions in high-sensitivity C-reactive protein (hs-CRP) and cardiac troponin T (cTnT) levels (Kleveland et al., 2016). The gene discussed is CRP; the disease is myocardial infarction.